Netrin-1 Compounds and Compositions Thereof for Treating Pulmonary Hypertension
AssigneeThe Regents of the University of California
InventorHua Cai
Life of this patent
Estimating the term…
Abstract
Disclosed herein are netrin-1 compounds and compositions thereof and methods of using thereof to treat pulmonary hypertension. In some embodiments, the present invention provides methods of treating, reducing, or inhibiting pulmonary hypertension or reducing a subjects mean pulmonary arterial pressure (mPAP) and/or the subjects right ventricular systolic pressure (RVSP), which methods comprise administering to the subject a therapeutically effective amount of one or more netrin-1 compounds.
Claims19
A peptide comprising, consisting essentially of, or consisting of SEQ ID NO:
- 1 as follows:
- X1-X2-X3-C-X4-X5-X6-X7-T-X8-G (SEQ ID NO:
- 1)
- wherein
- X1 is Ala, Asn, Cys, D-Cys, Ser, or Thr, preferably X1 is Cys, Ser, or Thr, wherein when X1 is Cys, it is linked, e.g., attached covalently or non-covalently to either the cysteine residue at the fourth amino acid position via a disulfide bond or an ethylene oxide compound;
- X2 is present or absent, and if present, X2 is Ala, Asp, Ile, Leu, Met, Phe, Pro, Trp, or Val, preferably X2 is Leu or Pro;
- X3 is present or absent, and if present, X3 is Asn, Arg, Asp, Cys, Gln, Glu, Gly, Ser, Thr, or Tyr, preferably X3 is Asn or Asp;
- X4 is Arg, His, or Lys, preferably X4 is Arg or Lys;
- X5 is Arg, Asp, Glu, His, Lys, Phe, Trp, or Tyr, preferably X5 is Asn, Asp, or His;
- X6 is Asn, Cys, Gln, Gly, Ser, Thr, Tyr, or Val, preferably X6 is Asn or Gly;
- X7 is present or absent, and if present, X7 is Asn, Gly, His, Ile, Thr, or Val, preferably X7 is Val;
- and
- X8 is present or absent, and if present, X8 is Ala, Asn, Ile, Leu, Met, Phe, Pro, Thr, Trp, or Val, preferably X8 is Ala;
- and
- wherein X2, X3, or both X2 and X3 are present, and when X1 is D-Cys, preferably the last amino acid residue at the C-terminal end is a D-amino acid, or both the glycine residue at the 10th amino acid position and the last amino acid residue at the C-terminal end are D-amino acids.
A method of treating, reducing, or inhibiting pulmonary hypertension in a subject, which comprises administering to the subject a therapeutically effective amount of one or more netrin-1 compounds according to claim 13.
A method of reducing a subject's mean pulmonary arterial pressure (mPAP) and/or the subject's right ventricular systolic pressure (RVSP), which comprises administering to the subject a therapeutically effective amount of one or more netrin-1 compounds according to claim 13.
A method of treating, reducing, or inhibiting right ventricular hypertrophy, medial wall thickening, and/or muscularization and cell proliferation in a subject, which comprises administering to the subject a therapeutically effective amount of one or more netrin-1 compounds according to claim 13.
A method of preserving or maintaining nitric oxide (NO) bioavailability while attenuating, reducing, or inhibiting reactive oxygen species (ROS) production caused by hypoxia and/or pulmonary hypertension in a subject, which comprises administering to the subject a therapeutically effective amount of one or more netrin-1 compounds according to claim 13.
A netrin-1 compound which is a peptide that has an amino acid sequence that comprises, consists essentially of, or consists of SEQ ID NO:
- 1 as follows:
- X1-X2-X3-C-X4-X5-X6-X7-T-X8-G (SEQ ID NO:
- 1)
- wherein
- X1 is Ala, Asn, Cys, D-Cys, Ser, or Thr, preferably X1 is Cys, D-Cys, Ser, or Thr;
- X2 is present or absent, and if present, X2 is Ala, Asp, Ile, Leu, Met, Phe, Pro, Trp, or Val, preferably X2 is Leu or Pro;
- X3 is present or absent, and if present, X3 is Asn, Arg, Asp, Cys, Gln, Glu, Gly, Ser, Thr, or Tyr, preferably X3 is Asn or Asp;
- X4 is Arg, His, or Lys, preferably X4 is Arg or Lys;
- X5 is Arg, Asp, Glu, His, Lys, Phe, Trp, or Tyr, preferably X5 is Asn, Asp, or His;
- X6 is Asn, Cys, Gln, Gly, Ser, Thr, Tyr, or Val, preferably X6 is Asn or Gly;
- X7 is present or absent, and if present, X7 is Asn, Gly, His, Ile, Thr, or Val, preferably X7 is Val;
- and
- X8 is present or absent, and if present, X8 is Ala, Asn, Ile, Leu, Met, Phe, Pro, Thr, Trp, or Val, preferably X8 is Ala;
- and
- wherein X2, X3, or both X2 and X3 are present.
Dependencies are inferred from the claim text.